anti-FGF23 antibody (Amgen)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Nameanti-FGF23 antibody (Amgen)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody

Mechanisms of ActionFibroblast growth factor 23 antagonists

TargetsFibroblast growth factor 23

Therapy Area/IndicationsKidney Failure, Chronic

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesAmgen Inc

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesAmgen Inc

Active IndicationsN/A

Inactive IndicationsKidney Failure, Chronic

ATC CodeN/A